Methylmalonic Acidemia (MMA) Market Report 2026

The methylmalonic acidemia (mma) market size has grown strongly in recent years. It will grow from $9.94 billion in 2025 to $10.52 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increase in rare disease awareness, rise in newborn screening programs, expansion of metabolic disorder research, improved diagnostic technologies, early genetic testing adoption.

The methylmalonic acidemia (mma) market size is expected to see strong growth in the next few years. It will grow to $13.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to growth in precision therapeutics, advancement in gene and enzyme replacement therapies, rising investment in rare disease drug pipelines, expanding telehealth-based metabolic monitoring, increasing focus on personalized nutrition management. Major trends in the forecast period include precision medicine-based therapy development, AI-assisted diagnosis and monitoring, cloud-based rare disease data integration, automated biomanufacturing for enzyme therapies, immersive medical training for metabolic disorders.

The rising incidence of metabolic disorders and vitamin deficiencies is expected to drive the growth of the methylmalonic acidemia (MMA) market in the coming years. Metabolic disorders are a set of conditions in which the body struggles to process certain nutrients, generate energy, or regulate chemical reactions within cells. Vitamin deficiencies arise when the body lacks sufficient amounts of specific vitamins needed for normal functioning. The increase in metabolic disorders and vitamin deficiencies is linked to unhealthy diets, sedentary lifestyles, and higher stress levels. Contemporary diets often contain high amounts of processed foods, sugars, and unhealthy fats while being low in essential nutrients, resulting in deficiencies in vitamins and minerals. Metabolic disorders and vitamin deficiencies, especially vitamin B12 deficiency, disrupt methylmalonyl-CoA metabolism, leading to the accumulation of methylmalonic acid and worsening methylmalonic acidemia (MMA). For example, in November 2024, the National Institutes of Health, a US-based government agency, reported that the prevalence of vitamin B12 deficiency rose from 4.6% to 5.2%, corresponding to an additional 507 cases between the third and fourth quarters of 2023. Consequently, the growing incidence of metabolic disorders and vitamin deficiencies is expected to propel the expansion of the methylmalonic acidemia (MMA) market.

The rising neonatal and pediatric population is expected to drive the growth of the methylmalonic acidemia market in the coming years. The neonatal and pediatric population includes newborns within the first 28 days of life and children below 18 years of age. This increase is primarily attributed to enhanced maternal healthcare and neonatal care services, which have improved survival rates and reduced infant mortality in developed countries. The expanding neonatal and pediatric population fuels the demand for early diagnosis and management of metabolic disorders through broader newborn screening programs. For example, in October 2025, the Australian Bureau of Statistics, a government agency based in Australia, reported that in 2024, a total of 292,318 births were registered, marking a 1.9% increase (an additional 5,320 births) compared to 2023, comprising 150,299 male and 142,019 female infants. Consequently, the growth of the neonatal and pediatric population is contributing to the expansion of the methylmalonic acidemia market.

Major companies in the methylmalonic acidemia (MMA) market are concentrating on developing innovative treatments, such as mRNA-based therapies, to enhance patient outcomes by addressing the underlying genetic causes of MMA and improving enzyme function to decrease the buildup of toxic metabolites in affected individuals. mRNA-based therapies are treatments that use messenger RNA to direct cells to produce specific proteins that can help prevent or treat diseases, including genetic disorders or infections. For example, in June 2024, Moderna, Inc., a US-based pharmaceutical and biotechnology company, received U.S. Food and Drug Administration (FDA) approval to include mRNA-3705 in the START pilot program, representing a significant milestone in advancing therapies for rare diseases. mRNA-3705 is an investigational treatment for methylmalonic acidemia (MMA) caused by MUT deficiency, aimed at restoring the deficient enzyme through mRNA technology. The therapy utilizes Moderna's proprietary lipid nanoparticle (LNP) system, also employed in the mRNA-3927 program for propionic acidemia. The FDA has granted mRNA-3705 orphan drug, fast track, and rare pediatric disease designations, supporting its accelerated development and clinical progression.

Major companies operating in the methylmalonic acidemia (mma) market are Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc AskBio, Selecta Biosciences Inc, BridgeBio Pharma Inc., VectivBio Holding AG, Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., LogicBio Therapeutics Inc., Moderna Inc., Wockhardt Limited, Supriya Lifescience Ltd., HemoShear Therapeutics LLC, Deccan Nutraceuticals Pvt Ltd, Genespire, Bluebird Bio Inc, Takeda Pharmaceutical Company Limited, Sanofi, Orphan Technologies Ltd, Ultragenyx Pharmaceutical Inc, HemoShear Therapeutics LLC.

North America was the largest region in the methylmalonic acidemia (MMA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (mma) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the methylmalonic acidemia (mma) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created moderate challenges for the methylmalonic acidemia market by increasing the cost of imported active pharmaceutical ingredients, medical nutrition products, and diagnostic reagents used in disease management. These cost pressures primarily affect hospital and pharmacy distribution channels and treatment centers in regions dependent on imports, including Asia-Pacific and parts of Latin America. Biotech therapy developers and specialty drug manufacturers also face margin pressure due to higher production and logistics expenses. However, tariffs have encouraged some companies to localize manufacturing and diversify supplier networks, which may improve long-term supply stability and regional production capabilities.

The methylmalonic acidemia (mma) market research report is one of a series of new reports that provides methylmalonic acidemia (mma) market statistics, including methylmalonic acidemia (mma) industry global market size, regional shares, competitors with a methylmalonic acidemia (mma) market share, detailed methylmalonic acidemia (mma) market segments, market trends and opportunities, and any further data you may need to thrive in the methylmalonic acidemia (mma) industry. This methylmalonic acidemia (mma) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder in which the body cannot properly break down certain proteins and fats due to a deficiency in the enzyme methylmalonyl-CoA mutase or its coenzyme, vitamin B12. Symptoms of MMA can vary in severity but often include vomiting, lethargy, poor feeding, developmental delays, seizures, and failure to thrive.

The primary indication types of methylmalonic acidemia (MMA) include acidosis, ketosis, hyperammonemia, hypoglycemia, hyperglycemia, neutropenia, and other related conditions. Acidosis is a state in which there is an excess of acid in the blood, resulting in a lower-than-normal pH level. There are various disorder types, such as homocystinuria, isolated methylmalonic acidurias, and combined methylmalonic aciduria. Treatment and management occur through multiple distribution channels, including hospitals, pharmacies, clinics, and other healthcare outlets.

The methylmalonic acidemia (MMA) market consists of revenues earned by entities by providing services such as medical management, dietary support, and vitamin and medication therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The methylmalonic acidemia market includes sales of hydroxocobalamin, vitamin B12 tablets, other pharmaceutical and therapeutic products, dietary products, and diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.